Jason Gerberry
Stock Analyst at B of A Securities
(4.18)
# 464
Out of 5,139 analysts
163
Total ratings
60.5%
Success rate
11.05%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.65 | +9.16% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $63.84 | +26.88% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $76.33 | +27.08% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $31.76 | +0.76% | 15 | Dec 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $230 → $247 | $169.41 | +45.80% | 6 | Nov 18, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $25.22 | +14.99% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.07 | +22.75% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $26.27 | +14.20% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $13.14 | +272.91% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $177.27 | -0.72% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.29 | -56.33% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $37.93 | -39.36% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $43.96 | +4.64% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $46.59 | +194.05% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $12.86 | -22.24% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $22.70 | +32.16% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $68.94 | +45.05% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $7.35 | +226.53% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $33.54 | -7.56% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $1.99 | +27,538.19% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $31.63 | -8.31% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $39.98 | +40.07% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $36.22 | -17.17% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,038.40 | -51.85% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.63 | +452.15% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $8.76 | +185.39% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.71 | +192.40% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.98 | +286.82% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.60 | +1,150.00% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $7.26 | +1,277.41% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $214.35 | -55.68% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $55.26 | +8.58% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $108.83 | -17.30% | 11 | Oct 17, 2019 |
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.65
Upside: +9.16%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $63.84
Upside: +26.88%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $76.33
Upside: +27.08%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $31.76
Upside: +0.76%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $230 → $247
Current: $169.41
Upside: +45.80%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $25.22
Upside: +14.99%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.07
Upside: +22.75%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $26.27
Upside: +14.20%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $13.14
Upside: +272.91%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $177.27
Upside: -0.72%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.29
Upside: -56.33%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $37.93
Upside: -39.36%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $43.96
Upside: +4.64%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $46.59
Upside: +194.05%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $12.86
Upside: -22.24%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $22.70
Upside: +32.16%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $68.94
Upside: +45.05%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $7.35
Upside: +226.53%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $33.54
Upside: -7.56%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $1.99
Upside: +27,538.19%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $31.63
Upside: -8.31%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $39.98
Upside: +40.07%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $36.22
Upside: -17.17%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,038.40
Upside: -51.85%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.63
Upside: +452.15%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $8.76
Upside: +185.39%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.71
Upside: +192.40%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.98
Upside: +286.82%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.60
Upside: +1,150.00%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $7.26
Upside: +1,277.41%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $214.35
Upside: -55.68%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $55.26
Upside: +8.58%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $108.83
Upside: -17.30%